A progressive daily ledger of Trump-world self-owns, legal pain, policy blowback, and bad-faith chaos.
Trump’s new pharmaceutical tariff regime is moving from headline to headache. Industry groups are warning about higher costs and investment risk, the White House has had to carve out exemptions and delayed timelines, and the policy is already setting off the usual scramble over who gets spared and who gets hit.
Why it matters: drug tariff backlash
Returning reader
Trump’s new pharmaceutical tariff regime is moving from headline to headache. Industry groups are warning about higher costs and investment risk, the White House has had to carve out exemptions and delayed timelines, and the policy is already setting off the usual scramble over who gets spared and who gets hit.
Read the complete verified updateComplete record
Newest first
Trump’s new pharmaceutical tariff regime is moving from headline to headache. Industry groups are warning about higher costs and investment risk, the White House has had to carve out exemptions and delayed timelines, and the policy is already setting off the usual scramble over who gets spared and who gets hit.
Truth standard
The linked reports preserve their sources, audit notes, confidence rating, corrections, and comments. The page Q&A below is restricted to those connected materials and will say when the evidence does not establish an answer.